Table 3 Summary of eligible studies on bone health, n = 3 studies
From: Late effects of high-dose methotrexate treatment in childhood cancer survivors—a systematic review
First author Year Country | Final cohort (male:female); diagnosis Cohort description | Age at diagnosis [years] | Follow-up [years] | Method | Effect of HD-MTX |
|---|---|---|---|---|---|
Lequin et al. 2002 The Nether-lands | 21 (12:9); ALL | Males: mean 6.3 ± 3.5 | Mean 9.6 (range 7.9–11.4) | DXA lumbar spine and total body (z-Score): BMD, BMDvol continuous variables | Group I vs. control group: ▪BMD, BMDvol: no sign. difference |
Study group: ▪Group I: HD-MTX (n = 21) | Females: mean 4.6 ± 2.7 | Follow-up: since end of treatment | |||
Control group: ▪nrv | |||||
Tillmann et al. 2002 UK | 28 (17:11); ALL | Study group: N/A | Mean 4.5 (range 1.5–7.1) | DXA lumbar spine and total body (z-Score): BMDvol continuous variables | Group I vs. II: ▪Lumbar BMDvol: no sign. Difference (trend: lower BMDvol in group I) |
Study group: ▪Group I: HD-MTX (n = 18) ▪Group II: No HD-MTX (n = 10) | age at testing: mean 10.7 ± 2.1 (range 5.7–14.7) | Follow-up: since end of treatment | |||
van der Sluis et al. 2000 The Netherlands | 23 (13:10); ALL | Mean 5.4 (range 1.9–12.4) | Mean 9.6 (range 7.9–11.4) | DXA lumbar spine and total body (z-Score): BMD, BMDvol continuous variables | Group I vs. control group: ▪BMD, BMDvol: no sign. difference |
Study group: ▪Group I: HD-MTX (n = 23) Control group: ▪nrv | Follow-up: since end of treatment |